Cartesian Therapeutics (RNAC) risk factors

53 risks, 4 new, 6 dropped, 8 reworded since the prior year. Cartesian Therapeutics faces clinical and commercial uncertainties regarding its lead mRNA product candidate Descartes-08 for autoimmune disease. The company addresses financial runway, tax loss carryforward limitations, and intellectual property enforcement risks.

55 risks. Cartesian Therapeutics faces significant clinical-stage risks, heavy reliance on internal and third-party biological manufacturing, extensive IP and patent protection dependencies, and capital-raising needs to fund operations into mid-2027.